MétaCan
Menu
Back to cohort
Record W3109242892 · doi:10.12927/hcpol.2020.26351

The Impact of Prescription Medication Cost Coverage on Oral Medication Use for Hypertension and Type 2 Diabetes Mellitus

2020· article· en· W3109242892 on OpenAlexafffundvenueabout
Razan Amoud, Kelly Grindrod, Martin Cooke, Mhd Wasem Alsabbagh

Bibliographic record

VenueHealthcare policy · 2020
Typearticle
Languageen
FieldMedicine
TopicMedication Adherence and Compliance
Canadian institutionsUniversity of Waterloo
FundersCanadian Institutes of Health Research
KeywordsMedical prescriptionMedicineDiabetes mellitusMedication adherenceType 2 Diabetes MellitusHealth insuranceType 2 diabetesFamily medicineHealth careInternal medicinePharmacology

Abstract

fetched live from OpenAlex

Background: No previous study, to the best of our knowledge, has examined both the time trend and impact of not having insurance or prescription medication cost coverage (PMCC) on the usage of type 2 diabetes and hypertension oral medications in Ontario and New Brunswick, Canada.Methods: We used data from the Canadian Community Health Survey (CCHS) from 2007 to 2014 to examine the time trend and impact of PMCC.A multivariable-adjusted logistic regression model was fitted.Results: The pseudo-cohort included 23,215 individuals representing a population of approximately 8.7 million people.Overall, 20.0% of respondents reported absence of PMCC.This proportion increased slightly from 19.6% (95% confidence interval [CI] 95% CI [17.5, 22.5]) to 20.7% (95% CI [16.9, 23.1]).Adjusted odds ratios (OR) showed that uninsured individuals were 23% less likely to use their medications (OR = 0.77, 95% CI [0.657, 0.911]).Conclusion: There was a slight decline in PMCC over time and this decline was associated with reduced use of medications for type 2 diabetes and hypertension. RésuméContexte : Aucune étude, à notre connaissance, n' a examiné à la fois la tendance temporelle et l'impact de l' absence de régime d' assurance ou de couverture du coût des médicaments d' ordonnance (CCMO) sur l' utilisation des médicaments oraux contre le diabète de type 2 et l'hypertension en Ontario et au Nouveau-Brunswick, au Canada.Méthode : Nous avons utilisé les données de l'Enquête sur la santé dans les collectivités canadiennes (ESCC) de 2007 à 2014 pour examiner la tendance temporelle et l'impact de la CCMO.Un modèle de régression logistique ajusté à plusieurs variables a été employé.Résultats : La pseudo-cohorte comprenait 23 215 individus représentant une population d' environ 8,7 millions de personnes.Dans l' ensemble, 20,0 % des répondants ont signalé ne pas avoir de CCMO.Cette proportion a légèrement augmenté, passant de 19,6 % (intervalle de confiance [IC] à 95% [17,5; 22,5]) à 20,7 % (IC à 95% [16,9; 23,1]).Les rapports de cote (RC) corrigés montrent que les personnes non assurées sont moins susceptibles, dans une proportion de 23 %, d' utiliser leurs médicaments (RC = 0,77, IC à 95% [0,657; 0,911]).Conclusion : Il y a eu une légère baisse de la CCMO au fil du temps et cette baisse est associée à une réduction de l' utilisation des médicaments pour le diabète de type 2 et l'hypertension. The Impact of Prescription Medication Cost Coverage on Oral Medication Use for Hypertension and Type 2 Diabetes Mellitus

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.011
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.823
Threshold uncertainty score0.356

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.011
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.003
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.139
GPT teacher head0.401
Teacher spread0.262 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2020
Admission routes4
Has abstractyes

Explore more

Same venueHealthcare policySame topicMedication Adherence and ComplianceFrench-language works237,207